Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Vermont Medical Center
About this trial
This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes include measuring changes in health-related quality of life, esophageal quality of life, toxicity, dosimetric outcomes, and pain.
Eligibility criteria
Qualifiers
Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
Disqualifiers
None
Trial design
Treatments tested in this trial
- Hybrid Palliative Radiation Therapy
Treatment groups
103 Participants
are divided into 1 treatment groupLocations
1University of Vermont Medical Center05401, BurlingtonVermont, United States
Sponsors and collaborators
University of Vermont Medical Center
Lead sponsor
Source ClinicalTrials.gov